Biotech · Private company
Evopoint Biosciences Inc.
Track this companyFree. Adds Evopoint Biosciences Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- Combination of Imipenem/Cilastatin and XNW4107Phase 3 · Complicated Urinary Tract Infection Including Acute PyelonephritisClinicalTrials.gov · fetched Nov 12, 2026
- Combination of Imipenem/Cilastatin and XNW4107Phase 3 · Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- Imipenem/Cilastatin/RelebactamPhase 3 · Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- MeropenemPhase 3 · Complicated Urinary Tract Infection Including Acute PyelonephritisClinicalTrials.gov · fetched Nov 12, 2026
- Imipenem/CilastatinPhase 1 · Bacterial InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- XNW28012Phase 1 · Metastatic Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- XNW4107Phase 1 · Bacterial InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- XNW4107, Imipenem/CilastatinPhase 1 · Bacterial InfectionsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic CancerPHASE1 · NOT_YET_RECRUITING · started Jul 30, 2026ClinicalTrials.gov NCT07707674 · fetched Nov 12, 2026
- Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)PHASE3 · UNKNOWN · started Mar 30, 2023ClinicalTrials.gov NCT05204368 · fetched Nov 12, 2026
- Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)PHASE3 · COMPLETED · started Jul 31, 2022ClinicalTrials.gov NCT05204563 · fetched Nov 12, 2026
- Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy SubjectsPHASE1 · COMPLETED · started Mar 25, 2021ClinicalTrials.gov NCT04802863 · fetched Nov 12, 2026
- To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.PHASE1 · COMPLETED · started Mar 2, 2021ClinicalTrials.gov NCT04801043 · fetched Nov 12, 2026
- Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal FunctionPHASE1 · COMPLETED · started Feb 25, 2021ClinicalTrials.gov NCT04787562 · fetched Nov 12, 2026
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/CilastatinPHASE1 · COMPLETED · started Jul 10, 2020ClinicalTrials.gov NCT04482569 · fetched Nov 12, 2026